SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-016452
Filing Date
2021-01-25
Accepted
2021-01-25 17:18:01
Documents
16
Period of Report
2021-01-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d111809d8k.htm   iXBRL 8-K 29921
2 EX-1.1 d111809dex11.htm EX-1.1 184096
3 EX-5.1 d111809dex51.htm EX-5.1 16052
7 GRAPHIC g111809dsp48.jpg GRAPHIC 3020
8 GRAPHIC g111809dsp49.jpg GRAPHIC 2001
  Complete submission text file 0001193125-21-016452.txt   417211

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20210120.xsd EX-101.SCH 3051
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20210120_lab.xml EX-101.LAB 18907
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20210120_pre.xml EX-101.PRE 11850
9 EXTRACTED XBRL INSTANCE DOCUMENT d111809d8k_htm.xml XML 3490
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 21550767
SIC: 2834 Pharmaceutical Preparations